Barrington Research Maintains Outperform on Cross Country Healthcare, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
Barrington Research analyst Kevin Steinke has maintained an Outperform rating on Cross Country Healthcare (NASDAQ:CCRN) but lowered the price target from $29 to $26.
November 29, 2023 | 4:13 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Barrington Research maintains an Outperform rating on Cross Country Healthcare but reduces the price target from $29 to $26.
The reduction in price target by Barrington Research, despite maintaining an Outperform rating, could lead to a negative perception among investors, potentially causing a short-term dip in the stock price of Cross Country Healthcare.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100